Smoking and Diabetes Attenuate Number of CD34 + Haematopoietic Stem Cells in Peripheral Blood of Patients with Advanced Peripheral Artery Disease.
Barbara SernekRok KamnikarMiran ŠebeštjenAnja BocVinko BocPublished in: International journal of molecular sciences (2023)
Peripheral artery disease (PAD) is a globally prevalent problem with limited treatment options, leaving up to a fifth of patients remediless. The emergence of new studies on cell therapy in recent years offers a new promising option for their treatment. Our aim was to explore how the number of CD34 + hematopoietic cells in the peripheral blood of PAD patients is associated with patients' functional as well as atherogenic factors. We selected 30 patients with advanced PAD, recorded their performance in a walking test in standard conditions and sampled their blood for further analysis with an emphasis on CD34 + cell selection and counting. No correlation of the CD34 + cell number was confirmed with any of the observed laboratory parameters. There was an association between the claudication distance and the number of CD34 + cells (r = -0.403, p = 0.046). The number of CD34 + cells differed between patients with and without type II diabetes ( p = 0.071) and between active smokers, past smokers, and non-smokers ( p = 0.035; p = 0.068, p = 0.051, respectively), with both smoking and presence of diabetes type II having a negative effect on the number of CD34 + cells. Our study demonstrated a dependence of the CD34 + cell number on the patient's characteristics.
Keyphrases
- cell therapy
- induced apoptosis
- stem cells
- end stage renal disease
- peripheral blood
- ejection fraction
- type diabetes
- newly diagnosed
- peripheral artery disease
- cell cycle arrest
- smoking cessation
- chronic kidney disease
- single cell
- nk cells
- prognostic factors
- cell death
- metabolic syndrome
- mesenchymal stem cells
- glycemic control
- bone marrow
- skeletal muscle
- adipose tissue
- case report
- pi k akt
- replacement therapy